Meeting
2018 ASCO Annual Meeting
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.
Authors
Oleg Gluz
Breast Center Niederrhein and University Clinics Cologne, Moenchengladbach, Germany
Oleg Gluz , Ulrike Nitz , Cornelia Liedtke , Matthias Christgen , Eva-Maria Grischke , Helmut Forstbauer , Michael Wilhelm Braun , Mathias Warm , John Hackmann , Christoph Uleer , Bahriye Aktas , Claudia Schumacher , Nikola Bangemann , Christoph Lindner , Sherko Kummel , Ronald E. Kates , Rachel Wuerstlein , Hans Heinrich Kreipe , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01815242
Citation
J Clin Oncol 36, 2018 (suppl; abstr 573)
DOI
10.1200/JCO.2018.36.15_suppl.573
Abstract #
573
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).
First Author: Lisa Katharina Katharina Richters
Poster
2015 ASCO Annual Meeting
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.
First Author: Oleg Gluz
Poster
2018 ASCO Annual Meeting
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
First Author: Volker Moebus
Poster
2015 Breast Cancer Symposium
Primary analysis of a randomized phase II, multicenter trial: Neoadjuvant weekly nab-paclitaxel 100mg/m2 followed by FE100C compared with docetaxel 75mg/m2 followed by FE100C for early breast cancer in Japan.
First Author: Takashi Kuwayama